Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)

Part of paid clinical trials in Portland, Oregon.

Sponsor
Oregon Health and Science University
Study ID
NCT04901325
Phase
PHASE2
Status
Completed

Conditions

  • Pyoderma
  • Pyoderma Gangrenosum
  • Skin Diseases
  • Skin Ulcer
  • Wound Heal

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • Baricitinib — DRUG
    Subjects with PG will be treated with 4 mg once daily of baricitinib for 24 weeks.

Study Details

An Open-Label, Proof-Of-Concept, Study of Baricitinib for the Treatment of Pyoderma Gangrenosum

Key Dates

Start date
Oct 3, 2023
Status verified
May 2025
Primary completion
Jan 5, 2025
Completion
May 7, 2025

Study Design

Enrollment
5 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Baricitinib for PG
    Subjects with PG will be treated with 4 mg once daily of baricitinib for 24 weeks in addition to starting stable dose (at least 2 weeks) of prednisone at 30 mg daily. Prednisone will be tapered based on a pre-established algorithm assessed by investigator.

Primary Outcome Measure

Healing [ Time Frame: Week 24 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Oregon Health and Science UniversityPortlandOregon97239-

Find similar trials in Portland, OR

By research site
Oregon Health and Science University· Portland, OR

Related Studies